[en] OBJECTIVE: Knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant recipients is lacking, particularly in terms of severity of the disease. The aim of this study was to describe the demographic, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 infection. DESIGN: We conducted an international prospective study across Europe on liver transplant recipients with SARS-CoV-2 infection confirmed by microbiological assay during the first outbreak of COVID-19 pandemic. Baseline characteristics, clinical presentation, management of immunosuppressive therapy and outcomes were collected. RESULTS: 57 patients were included (70% male, median (IQR) age at diagnosis 65 (57-70) years). 21 (37%), 32 (56%) and 21 (37%) patients had one cardiovascular disease, arterial hypertension and diabetes mellitus, respectively. The most common symptoms were fever (79%), cough (55%), dyspnoea (46%), fatigue or myalgia (56%) and GI symptoms (33%). Immunosuppression was reduced in 22 recipients (37%) and discontinued in 4 (7%). With this regard, no impact on outcome was observed. Forty-one (72%) subjects were hospitalised and 11 (19%) developed acute respiratory distress syndrome. Overall, we estimated a case fatality rate of 12% (95% CI 5% to 24%), which increased to 17% (95% CI 7% to 32%) among hospitalised patients. Five out of the seven patients who died had a history of cancer. CONCLUSION: In this European multicentre prospective study of liver transplant recipients, COVID-19 was associated with an overall and in-hospital fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. A history of cancer was more frequent in patients with poorer outcome.
Disciplines :
Chirurgie Gastroentérologie & hépatologie
Auteur, co-auteur :
Becchetti, Chiara
Zambelli, Marco Fabrizio
Pasulo, Luisa
Donato, Maria Francesca
Invernizzi, Federica
Detry, Olivier ; Université de Liège - ULiège > Département des sciences cliniques > Pathologie chirurgicale abdominale et endocrinienne
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020;120:998-1000.
Deng X, Yang J, Wang W, et al. Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa578. [Epub ahead of print: 15 May 2020].
COVID-19 Dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). Available: https:// coronavirus. jhu. edu/ map. html
WHO. Coronavirus disease (COVID-19) pandemic. Available: https://www. who. int
Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 2020. doi:10.1002/hep.31281. [Epub ahead of print: 16 Apr 2020].
Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2:100113.
Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant 2020. doi:10.1111/ajt.15869. [Epub ahead of print: 17 Mar 2020].
Bhoori S, Rossi RE, Citterio D, et al. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol 2020;5:532-3.
Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020. doi:10.1111/ ajt.15929. [Epub ahead of print: 16 Apr 2020].
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14.
Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US EpiCenter. Am J Transplant 2020. doi:10.1111/ajt.15941. [Epub ahead of print: 24 Apr 2020].
Kumar D, Tellier R, Draker R, et al. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003;3:977-81.
AlGhamdi M, Mushtaq F, Awn N, et al. Mers CoV infection in two renal transplant recipients: case report. Am J Transplant 2015;15:1101-4.
Fishman JA, Grossi PA. Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient Flatteningthecurve. Am J Transplant 2020;382.
Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.
Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998-1004.
Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-Related liver functional abnormality. Clin Gastroenterol Hepatol 2020;18:1561-6.
Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 2020. Available: https://www. who. int/ publications-detail/ globalsurveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interimguidance
Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 2019;201160:201160.
Rabkin JM, de La Melena V, Orloff SL, et al. Late mortality after orthotopic liver transplantation. Am J Surg 2001;181:475-9.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-33.
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949:105949.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.0994. [Epub ahead of print: 13 Mar 2020].
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA 2020. doi:10.1001/jama.2020.6775. [Epub ahead of print: 22 Apr 2020].
Zheng Z, Peng F, Xu B, et al. Risk factors of critical &mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020.
Webb GJ, Moon AM, Barnes E, et al. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020. doi:10.1016/ S2468-1253(20)30125-4. [Epub ahead of print: 24 Apr 2020].
Zhang J, Yu M, Tong S, et al. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol 2020;127:104392.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-7.
Desai A, Sachdeva S, Parekh T, et al. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 2020;6:557-9.
Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020;5:33.
American Association for the Study of Liver Diseases. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic, 2020. Available: https://www. aasld. org/ sites/
Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-A systematic review of current evidence. Ecancermedicalscience 2020;14:1022.
Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020;200432:200432.
